The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
|Webcasts|August 5, 2020
Virtualizing Clinical Trials in a Pandemic: Lessons Learned and What It Means to the Future of R&D
Author(s)Advanced Clinical
In this webcast we will explore how the required adoption of virtual recruiting, telemedicine, remote monitoring and at-home healthcare visits have taught us valuable lessons about how to run more agile and adaptive trials; and how these learnings will shape the future of R&D. Live: Thursday, Sept. 24, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after airing until Sept. 24, 2021.
Register free:
Event Overview:
The impact of COVID-19 on clinical trials has been substantial. For example, travel bans and site closures have forced a rapid shift in the running of physical clinical investigative sites toward purely virtual environments. While the concept of virtual clinical trials has been around for a number of years, the decision to actually run a trial has remained somewhat optional. Now, sponsors are now finding themselves forced into either fully virtualized trials and/or hybrid trials, out of necessity. However, there are silver linings – especially when it comes to the potential for adapting quickly to unforeseen situations like remaining efficient and profitable amidst a pandemic.
In this webcast we will explore how the required adoption of virtual recruiting, telemedicine, remote monitoring and at-home healthcare visits have taught us valuable lessons about how to run more agile and adaptive trials; and how these learnings will shape the future of R&D.
Key Learning Objectives:
- How COVID-19 has impacted trial operations across the globe
- How trial sites have adapted through the use of virtual trial elements
- The challenges both sponsors and CROs have faced in this process – and how to overcome them
- Which technologies/solutions generate the most benefits, and which ones do not
- How lessons learned during COVID-19 can be incorporated into clinical operations plans and protocols to ensure adaptiveness and R&D efficiencies in the face of future crises
Speakers: Graham Belgrave, Senior Vice President, Head of European Operations, Advanced Clinical
Domantas Gurevicius, Senior Director, Clinical Monitoring, Advanced Clinical
Time and date: Thursday, Sept. 24, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
On demand available after airing until Sept. 24, 2021.
Sponsor: Advanced Clinical
Register free:
Related to this article
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
3
Where AI Governance in Clinical Development Falls Short
4
Syneos Health, Optum Partner on Adaptive Clinical Development Model
5